Similis Bio will handle the cell line development, analytics, and process development. Credit: Tatiana / Pixabay.

JSR Life Sciences’ business unit Similis Bio is planning to collaborate with Novel351k for the development of three biosimilar programmes targeting cancer and autoimmune diseases.

Under the terms of the initial deal, Similis Bio will handle the development of cell lines, analytics, process development, and cGMP production. This will lead to pharmacokinetics/pharmacodynamic clinical trials.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Using its regulatory and clinical strategies knowledge, Novel351k will accelerate the programmes development toward commercialisation.

The company’s strategy expedites the innovation, development, and commercialisation of drugs by providing affordable access to biologics.

Similis Bio head and JSR Life Sciences senior vice-president John Gabrielson said: “We launched Similis to make a wider selection of biosimilars available to patients, and we look forward to working with the Novel351k team on this important endeavour.

“This unique partnership combines Similis’ broad CMC expertise and Novel351k’s innovative clinical approach, underscoring our goal of accelerating the delivery of life-saving medicines to patients at lower costs.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The companies expect the collaboration to help progress the programmes to late-stage development activities and commercial manufacturing.

According to JSR Life Sciences, the therapies developed under the collaboration have more than $15bn current annual market value.

The co-development deal between Similis Bio and Novel351k is expected to be valued at $100m including development milestones and royalties, for over ten years.

Novel351k believes that the collaboration with JSR Life Sciences and Similis Bio will help reduce the cost structures to develop biosimilars.

Novel351k founder and chief scientific officer Sarfaraz Niazi said: “Novel351k supports the adoption of groundbreaking scientific approaches to reduce redundant testing and to accelerate the development of biosimilars.

“To that end, we aim to create a positive, measurable impact through our development and manufacturing model with world-class partners.”